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single cause, that which is the product of several,
and the majority of our controversies come from
that“
Baron Justus von Leibig (1803–1873).Summary
Despite level I evidence that carotid endarterectomy
(CEA) confers significant benefit over ‘best medical
therapy’, the paradox remains that the very operation
undertaken to prevent stroke (in the long-term) is
associated with a small, but important risk of stroke in
the peri-operative period. This paradox has, of course,
been recognised for more than 50 years. However, the
debate as to how stroke and other cardiovascular
complications might be prevented following CEA
remains largely unresolved and has been inappropri-
ately dominated by ‘single-issue’ subjects. These
include; choice of anaesthesia, traditional versus
eversion endarterectomy, dose of aspirin, shunt
usage, shunt thresholds, patching, tacking sutures,
peri-operative monitoring, sinus nerve blockade and
heparin reversal. Many of these issues are now largely
irrelevant, already resolved or simply unresolvable.
Their enduring persistence has, however, compro-
mised the evolution of newer and more novel
strategies for reducing peri-operative cardiovascular
morbidity and mortality.
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general anaesthesia. The literature abounds with
claims that CEA under LRA confers significant benefit,
but a 2004 meta-analysis of the seven available
randomised trials continues to show no significant
difference in outcome.1 However, a systematic review
of the 41 non-randomised trials1 showed that CEA
under LRA conferred significant reductions in: (i) any
stroke (2.0 versus 4.8%), (ii) death/any stroke (2.4
versus 5.8%), (iii) myocardial infarction (1.1 versus
3.3%), (iv) pulmonary complications (0.4 versus 2.1%)
and (v) a reduced requirement for shunting (13.3
versus 49.5%). Fortunately, this is one of the few
single-issue subjects where a large, well-designed
randomised trial (GALA) is underway and will
certainly guide practice in the future.
However, advocates of LRA must also recognise
that while CEA under LRA is undoubtedly the ‘gold-
standard’ for predicting who needs a shunt, haemo-
dynamic failure is actually responsible for!20% of all
intra-operative strokes.2 Accordingly, reliance upon
LRA (for general quality control or monitoring) will
not prevent the other 80% of thromboembolic intra-
operative strokes and few (if any) of the post-operative
ones, unless they are associated with post-endarter-
ectomy hypertension. Some other monitoring or
quality control strategy will be required to achieve
this goal. Accordingly, the most important future
benefit of CEA under LRA may be the potential for
significantly reducing early cardiovascular morbidity,
especially hypertension. In that respect, alone, the data
from GALA will assume considerable importance.
Until then, the available evidence suggests that
surgeons can perform CEA under either LRA or
general anaesthesia according to individual
preference.
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enduring controversy. This debate largely arose
because a subgroup analysis of the NASCET database3
suggested that CEA patients receiving low dose
aspirin (!325 mg daily) incurred a higher operative
risk (6.9 versus 1.8%) compared with patients receiv-
ing higher doses (650–1300 mg). In response to this
unplanned secondary analysis, the ACES study
randomisedO2500 patients and showed the converse
to be true.4 More importantly (especially from a
practical point of view), an increasing proportion of
cardiovascular patients are now prescribed chronic
Clopidogrel therapy (sometimes in combination with
aspirin). This is largely due to the small, but significant
reduction in vascular death and/or non-fatal stroke/
MI observed in the CAPRIE study.5 However, the
recently published MATCH study (clopidogrel alone
versus aspirinCclopidogrel in patients with a prior
history of stroke/TIA) has shown that chronic combi-
nation antiplatelet therapy does not reduce the long-
term risk of stroke, but does increase the risk of
life-threatening bleeding.6 This is an important finding
because chronic Clopidogrel usage trebles the bleed-
ing time, while aspirin and clopidogrel (in combi-
nation) confers a five-fold increase.7 Accordingly,
much of the debate regarding the choice and dose of
antiplatelet therapy is largely resolved. Low dose
aspirin remains the first-line agent in CEA patients
and aspirin should not be stopped prior to surgery or
be replaced with warfarin. Combination aspirin and
clopidogrel therapy should generally be avoided and
any patient receiving chronic Clopidogrel (on its own)
should probably stop this medication at least 7 days
before CEA and resume aspirin therapy wherever
possible.
The most enduring single-issue subject, however,
remains the role of shunting. Few randomised trials
have been performed, most have been methodologi-
cally flawed, so that meaningful interpretation of the
data is all but impossible.8 Few surgeons now
advocate a policy of ‘never’ shunting, so that the
battle lines are drawn between the ‘routine’ and
‘selective’ shunters, whose differences are now vir-
tually irreconcilable. So who is on the side of the
righteous? In fact, if one critically analyses the
rationales underlying shunting, the debate is actually
fairly straightforward. If you truly believe in a policy
of selective shunting, then the only method for
ensuring that you have reliably identified patients at
risk of haemodynamic failure during carotid clamping
is to perform CEA under LRA. No other monitoring
modality can (or will) accurately predict who needs a
shunt and surgeons, quite simply, have to accept this
unpalatable fact. Accordingly, unless the surgeon isEur J Vasc Endovasc Surg Vol 29, April 2005motivated towards changing practice towards per-
forming CEA under LRA (which seems the most
obvious strategy for selective shunters), it is probably
safer to advocate a policy of routine shunting.
Arguments that shunting is a regular cause of intimal
injury or that shunts impede access etc. are largely
over-exaggerated by the pro-LRA lobby. As far as this
author is concerned, the shunt debate has inappropri-
ately dominated practice to the detriment of virtually
everything else. There are other, far more important,
factors that influence the operative risk.
On a par with the intensity of the shunt debate is the
parallel controversy regarding the role of patching.
Moreover, having touched on the subject of patching,
one inevitably raises the question as to whether
eversion endarterectomy should be the preferred
option. Despite its enduring nature, there is more
evidence-based data to guide practice in this area. The
2004 Cochrane Overview clearly shows that a policy of
routine patching is significantly preferable to routine
primary closure.9 Routine patching conferred a three
to fourfold reduction in peri-operative stroke/throm-
bosis and late stroke/restenosis 9 and there was no
evidence that patch type (prosthetic, vein) influenced
outcome.10 Thus, for those surgeons who seek to
modify surgical practice (based on evidence), the case
for always closing the arteriotomy primarily cannot
now be sustained. Accordingly (as with the shunt
debate), the real argument is whether the arteriotomy
should be patched selectively or routinely. No ran-
domised trial has ever addressed this question, simply
because it remains totally impossible to get a group of
surgeons to agree consensus criteria for selective
patching!
Surgeons must, therefore, make their own decision
and accept that this is probably another issue that is
never going to be resolved scientifically. Although, (by
training) I am a routine patcher, intuitively I have to
accept that not everyone needs a patch. However,
unlike the invaluable (and otherwise infallible) role of
LRA for guiding selective shunt deployment, the
surgeon has no reliable way of knowing which
patients should be patched or not. Moreover, as with
the shunt debate, arguments that the risks of vein
patch rupture or patch infection mitigate against
patching are largely over-stated. These risks (!1%
overall) have to be compared with the systematic
evidence demonstrating the much higher risks of early
thrombosis and late stroke associated with primary
closure.9 Finally, provided the arteriotomy is closed
with a patch, systematic reviews of the randomised
trials show that early and long-term outcomes (stroke,
restenosis etc.) are not improved by eversion endarter-
ectomy.11 Thus, one can reasonably conclude that, with
Weapons of Myth and Distraction 331the exception of advocating a policy of routine
primary closure, surgeons can patch the arteriotomy
selectively or routinely (with whatever patch material
they prefer) or perform an eversion endarterectomy, in
the knowledge that they cannot be criticised on the
currently available evidence.
Sinus nerve blockade is another enduring contro-
versy. Four randomised trials have now addressed this
question, but their findings (to-date) have hardly
influenced clinical practice. Only one found that
sinus nerve blockade significantly reduced intra-
operative variations in blood pressure.12 Unfortu-
nately, this study was limited by only randomising
40 patients and there was no data regarding blood
pressure control in the early post-operative period.
Three other studies showed no evidence of any
significant reduction in the incidence of intra-operat-
ive hypotension requiring treatment though, para-
doxically, the lowest blood pressures were seen in
patients undergoing sinus nerve division.13 Two
studies observed that patients randomised to sinus
nerve blockade were more likely to suffer hyperten-
sion in the early post-operative period, presumably
following sinus reinnervation.14,15 Accordingly, there
is really no debate any more. There is no systematic
evidence supporting the routine use of sinus nerve
blockade in modern carotid surgical practice and sinus
nerve division should be avoided.
Another longstanding debate is whether heparin
should be reversed following flow restoration. As
recently as 1994, 54% of US surgeons and 26% of
European surgeons routinely administered protamine
at the end of arterial reconstructions.16 Only one
randomised trial has attempted to answer this ques-
tion during CEA (suspended after recruiting 65
patients.17) Although, neck drain losses were signifi-
cantly reduced in protamine-reversed patients, this
study was abandoned because three strokes followed
early post-operative carotid thrombosis in protamine-
reversed patients, in whom no technical error was
identified at re-exploration. Although one occurred in
a non-randomised patient, the authors felt that it was
unethical to continue. A number of non-randomised
studies have reported contradictory findings regard-
ing haematoma formation, but two have reported an
increased risk of stroke in protamine-reversed
patients.18,19 More recently, the GALA Investigators
have performed an interim analysis on the use of
heparin-reversal in 938 patients in the study.20 This
showed that outcomes (peri-operative stroke, death,
haematoma, re-exploration) were no different. Accord-
ingly, although the overall data are not particularly
robust, the available evidence suggests that there is no
systematic evidence that routine heparin-reversal isbeneficial to the CEA patient. Surgeons can, however,
administer protamine (selectively) according to indi-
vidual preference.
The final controversy, and one which this author
thinks has been inappropriately lost amid the battle-
field of shunt/patch debates, is the role of peri-
operative monitoring and quality control assessment.
It seems slightly ridiculous that vascular surgeons will
spend up to 4 h doing a femoro-distal bypass and
check that everything is technically satisfactory using
completion angiography and then not apply the same
principle to CEA. This is despite increasing awareness
that inadvertent technical error complicates up to two-
thirds of all peri-operative strokes,21 second, there is
often not much one can do once the stroke has
occurred and third, the outcomes are frequently
devastating and ultimately irreversible.
To-date, no randomised trials have been performed,
largely because there is no agreement as to what
constitutes the most appropriate monitoring policy.
There are a number of reasons why no consensus has
emerged. First, virtually every monitoring modality
has been used to develop thresholds for shunting,
even though haemodynamic failure is a relatively rare
cause of intra-operative stroke. With the exception of
transcranial Doppler (TCD), none have been devel-
oped to identify embolisation, which is now accepted
to be the principal cause of peri-operative stroke.
Second, is the naive assumption that there must be one
single and ‘all superior’ monitoring modality to the
exclusion of all others. Third (and most important) is a
simple failure to ask the right questions.
For example, CEA under LRA will undoubtedly
prevent haemodynamic failure during carotid clamp-
ing (because that is an appropriate question to ask of
it). However, it will neither prevent stroke due to
embolisation of luminal thrombus following restor-
ation of flow, nor early post-operative thrombosis. In
our centre, we were surprised to observe that the
majority of intra-operative strokes followed embolisa-
tion of thrombus adherent to the endarterectomy zone
following flow restoration (despite irrigation and
venting). The source of these thrombi was found to
be bleeding from the vasa vasorum on to the highly
thrombogenic endarterectomy zone.22 Having recog-
nised this, intra-operative stroke has now been
virtually abolished by simply adding completion
angioscopy to our intra-operative monitoring proto-
col. Again, ask the important question and tailor
monitoring and quality control modalities accordingly.
Similarly, stroke due to post-operative carotid throm-
bosis (POCT) complicates 2–3% of CEAs worldwide
and was previously thought to be unpreventable.
However, research from a number of centres aroundEur J Vasc Endovasc Surg Vol 29, April 2005
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of increasing embolisation before the onset of any
neurological deficit.23–28 Accordingly, detection of
high rate embolisation (using TCD) might enable this
‘window of opportunity’ to be exploited pharmaco-
logically (e.g. incremental Dextran therapy) so as to
prevent progression onto thrombosis and major
stroke. More recent evidence also suggests that
POCT might even be prevented in the future by the
administration of a single 75 mg dose of clopidogrel
(in addition to regular aspirin) the night before
surgery.29 This is because the platelets of patients
with higher rates of embolisation following CEA
appear to be more sensitive to ADP.30 Accordingly,
targeted modification of pre-operative antiplatelet
therapy could be an innovative way of preventing
this devastating complication.
In summary, in the five decades since CEA was first
introduced, the debate about how to reduce the
operative risk has been totally dominated by ‘single-
issue’ subjects. Clearly some are important, but many
are now either irrelevant or not solvable. More
importantly, their enduring persistence has prevented
other more useful practices and strategies from
emerging. To this author, the ‘hot topics’ are; (i)
establishing whether CEA under LRA reduces early
cardiovascular morbidity (especially hypertension),
(ii) evaluating the role of dual antiplatelet therapy
immediately prior to surgery in preventing POCT and
(iii) defining the role of targeted monitoring and
quality control. Out in the cold should be consigned
any debate regarding prediction of shunt thresholds
other than LRA, sinus nerve blockade, aspirin dose,
whether aspirin should be stopped pre-operatively
and heparin reversal. The ‘titans’, (shunting and
patching) will, of course, remain. Perhaps we as
surgeons should accept that unless we are prepared
to do the appropriate trials (which remains highly
unlikely), we should simply accept that the opposing
viewpoints are now virtually irreconcilable, other than
acknowledging that the available evidence cannot
support routine ‘never’ shunting and routine ‘never’
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